Abstract
TECHNICAL ABSTRACT: The aim of this work is to highlight the importance of the early characterization of physico-chemical properties to design an intravenous infusion regimen for a poorly water-soluble model compound. Compound X is a crystalline, poorly water-soluble weak base with a pH-dependent solubility profile. Due to its extremely low solubility above pH 6, the main challenge was to develop a suitable intravenous formulation for delivering high doses of compound X while minimizing the risk of precipitation upon injection into the blood (pH 7.4). A systematic approach, including formulation screening using minimum amounts of drug substance and evaluation of precipitation potential at the injection site, was employed in early discovery stages to identify a suitable infusion regimen for compound X in various preclinical models. More than 60 formulation variants were screened for solubility, pH, and precipitation potential using less than 150 mg of compound. Evaluation of precipitation potential upon injection was based on the calculation of the effective concentration at the injection site. Based on the results from formulation screening and the calculation of the effective concentration at the injection site, an intravenous infusion regimen was designed to overcome the precipitation upon injection risk associated with the poor physico-chemical properties of this compound.
LAY ABSTRACT: This work highlights the impact of the physico-chemical properties of a poorly water-soluble compound on the design of high-dose intravenous infusion regimens for preclinical development. Crystalline compounds, especially weak bases, with poor aqueous solubility have a high tendency to precipitate upon injection into the blood (pH 7.4). The main challenge was to develop a suitable intravenous formulation for delivering high doses of such crystalline, poorly water-soluble, weakly basic compounds. A combination approach, including formulation screening using minimum amounts of drug substance and evaluation of precipitation potential at the injection site, was employed in early discovery stages to identify a suitable infusion regimen for various animal models. Based on the results from formulation screening and the calculation of the effective concentration at the injection site, a suitable intravenous infusion regimen was designed to overcome the precipitation upon injection risk associated with the poor physico-chemical properties of this compound.
- © PDA, Inc. 2010
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.